At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 240 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate
In Brief
A Phase 2 clinical trial evaluating adalimumab and ABT-122 for Psoriatic Arthritis. Completed, enrolled 240 participants.
Detailed Summary
This study is a Phase 2 randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group study designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple doses of ABT-122 in participants with active PsA who are inadequately responding to MTX treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartApr 2015
Primary CompletionJul 2016
TodayJul 2026
First PostedJan 28, 2015
Enrollment StartApr 28, 2015
Primary CompletionJul 4, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.4 years ago
Interventions
adalimumabbiological
ABT-122biological